Loading…

Lonza Group AGLONN.SWCompetitor analysis, valuation and peers

Switzerland · CHF·Health Care›Biotechnology

Swiss contract development and manufacturing organization (CDMO) making biologics, small molecules and cell/gene therapies for pharma clients.

≈ A Swiss Catalent/Samsung BiologicsMomentum leader 92
Mkt cap
$53.9B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$106M
20-day average traded
Fwd P/E
36.1×
forward earnings
ROIC−WACC
+4.2 pp
WACC 6.3%
Hurdle
+8 pp
Req g minus delivered
Official | Implied
BBB+ / A+
agencies · bond market
Next earnings
70 days
27 Jan 2027
Close · CHFCHF 666.60
1D+0.5%
1W+0.5%
1M+6.7%
3M+12.6%
6M+35.6%
YTD+23.9%
1Y+22.4%
ATR %1.7%
52w lowhigh1.3% off high

What Lonza does

Swiss contract development and manufacturing organization (CDMO) making biologics, small molecules and cell/gene therapies for pharma clients.

Is paid by drug developers to produce their medicines under multi-year manufacturing agreements, often with upfront fees and minimum volumes, so revenue depends on how fully its plants are booked. Biologics, made in large bioreactors, are the core. The 2024 purchase of Genentech's Vacaville plant in California added large-scale capacity.

In one line: A Swiss Catalent/Samsung Biologics.

Products and services

  • Biologics manufacturing
  • Small molecule manufacturing
  • Cell & gene therapy manufacturing
  • Capsules/health ingredients

Customers

  • Large pharma companies
  • Biotech companies

Where it sits in the supply chain

  • Health care
  • Pharmaceutical services (CDMO)
  • Biologics, small molecule & cell/gene…

What could go right

  • Biologics/GLP-1 outsourced manufacturing demand
  • Cell & gene therapy market growth

What could go wrong

  • Large capex/utilization risk
  • Customer concentration in large pharma contracts

Moat: narrow (scale, process know-how, customer qualification). Complex, regulator-qualified biologics manufacturing capacity is costly and slow for pharma clients to replicate.

Headquarters: Basel, Switzerland · Founded: 1897 · Employees: 16,866

Named competitors

Lonza at a glance

Size Lonza (LONN.SW) is a Switzerland Health Care company (Biotechnology) with a market value of $53.9B, the 8th largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 666.60 on 18 Nov 2026.

Performance Over six months the shares gained 35.6%, against +23.6% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 6th highest of 15 in its peer set.

Growth Revenue fell 10.8% over the last twelve months (peer median +13.9%); the operating margin is 24.6% (peer median 27.3%).

Valuation It trades at 36.1× forward earnings against a peer median of 25.2× (2nd most expensive of 11).

Price implies For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.2 points above its cost of capital (6.3% WACC).

Credit Lonza has 5 bonds outstanding ($3.55B), rated BBB+ by the agencies and trading like A+ at a weighted spread of 72 bp.

Next results Next results expected around 27 Jan 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026LONN.SW 134Peer median 123
Six months, rebased to 100: Lonza against the median of its 14 peers (local-currency closes).

Lonza financials

Reported figures in CHF; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCHF 6.33BCHF 6.53BCHF 5.48BCHF 6.72BCHF 6.22B
Revenue growth—+19%-18%+8%—
Gross profitCHF 2.31BCHF 2.30BCHF 1.97BCHF 1.82BCHF 2.30B
EBITDACHF 2.15BCHF 2.03BCHF 1.56BCHF 1.48BCHF 1.95B
Net income-CHF 110M-CHF 275MCHF 636MCHF 654MCHF 1.22B
Free cash flowCHF 215M-CHF 152M-CHF 72.0M-CHF 234M-CHF 791M
Capital expenditureCHF 1.23BCHF 1.38BCHF 1.42BCHF 1.68BCHF 1.87B
Total debtn/aCHF 4.54BCHF 5.12BCHF 3.13BCHF 2.59B

Quarterly statements and history in the cockpit →

Lonza competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%-20%0%+20%ARGX207940CSLIQVNTRAMRNA068270GMAB2269BNTXNBIXLONN.SW6-month return →1-month return →
Up and to the right = strong over both horizons. Lonza is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%+75%20×30×40×ARGX207940CSLIQV068270GMABUTHR2269NBIXGILDLONN.SWRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Lonza is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%0%50%100%150%ARGX207940CSLIQV068270UTHR2269LONN.SWGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Lonza is the large dot.

Lonza competitors and peer comparison

Head to head with its named competitors (LONN.SW vs 207940.KS vs 2269.HK vs TMO)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Lonza LONN.SW$53.9B+36%-11%25%36.1×15.6%
Samsung Biologics 207940.KS$48.7B-6%-20%43%34.4×7.0%
Wuxi Bio 2269.HK$23.1B+35%+22%32%26.5×20.8%
Thermo Fisher Scientific TMO$257B+53%+8%19%25.7×21.3%

How Lonza compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Lonza against its 14 peers (data as of 18 Nov 2026)
MeasureLONN.SWPeer medianRank in peer set
1-month return+6.7%+2.9%6th highest of 15
6-month return+35.6%+23.6%6th highest of 15
Distance from 52-week high-1.3%-12.8%highest of 15
Revenue growth (TTM)-10.8%+13.9%3rd lowest of 15
Operating margin24.6%27.3%6th lowest of 15
Forward P/E36.1×25.2×2nd most expensive of 11
Growth the price implies (Req g, 7 yrs)15.6%8.8%3rd most demanding of 11
Growth delivered (Del g)+7.7%+18.5%3rd lowest of 11
Hurdle (Req g minus delivered)+7.9 pp-8.7 pp2nd most demanding of 11
ROIC minus cost of capital+4.2 pp+2.2 pp6th highest of 15
EV / EBITDA22.8×16.4×5th most expensive of 11
Net debt / EBITDA1.7×0.4×4th most indebted of 11
Bond spread72 bp98 bptightest of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Lonza LONN.SWSwitzerland$53.9B+36%-11%25%36.1×15.6%+7.7%
argenx SE Sponsored ADR ARGXUnited States$59.1B+17%+71%29%29.0×11.7%+151.4%
Samsung Biologics 207940.KSSouth Korea$48.7B-6%-20%43%34.4×7.0%+31.4%
CSL CSL.AXAustralia$63.7B+102%-2%26%21.5×6.8%+11.0%
Iqvia IQVUnited States$42.5B+50%+9%14%18.7×16.8%+7.5%
Natera NTRAUnited States$42.0B+41%+37%-9%n/an/an/a
Moderna MRNAUnited States$79.6B+309%+13%-116%n/an/an/a
Celltrion 068270.KSSouth Korea$34.9B+12%+40%32%33.9×10.6%+17.6%
Genmab A/S GMAB.CODenmark$30.8B+103%+15%31%40.9×11.6%+19.5%
United Therapeutics UTHRUnited States$24.6B+2%+2%44%23.9×0.3%+16.5%
Wuxi Bio 2269.HKHong Kong$23.1B+35%+22%32%26.5×20.8%+30.2%
BioNTech SE Sponsored ADR BNTXUnited States$20.6B-8%-21%-61%n/an/an/a
Neurocrine Biosciences NBIXUnited States$16.5B+5%+38%25%18.0×-1.5%+22.3%
BridgeBio Pharma BBIOUnited States$15.2B+14%+167%-37%n/an/an/a
Gilead Sciences GILDUnited States$210B+30%+7%38%19.9×-2.4%+3.6%

Lonza bonds and credit

Lonza has 5 bonds outstanding with $3.55B face value. The agencies rate it BBB+; its bonds trade like A+. Weighted yield 4.17%, a spread of 72 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Lonza's main competitors?
Named competitors: Samsung Biologics (207940.KS), Catalent (private) (private or unlisted), WuXi Biologics (2269.HK), Thermo Fisher (Patheon) (TMO). The cockpit's measured peer set (industry) also includes argenx SE Sponsored ADR (ARGX), Samsung Biologics (207940.KS), CSL (CSL.AX), Iqvia (IQV), Natera (NTRA), Moderna (MRNA).
Is Lonza expensive compared with its peers?
On forward p/e it trades at 36.1× against a peer median of 25.2×, 2nd most expensive of 11 in its peer set. For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Lonza stock performed?
Over six months to 18 Nov 2026 the shares returned +35.6% against +23.6% for the median peer; over one year +22.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.